$-1.57
(Market cap
$2,732 Mln
Recently Viewed
Clear AllMarket cap
$2,732 Mln
Revenue (TTM)
$460 Mln
P/E Ratio
--
P/B Ratio
3.8
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-2.4
Debt to Equity
0.3
Book Value
$6.5
EPS
$-1.6
Face value
--
Shares outstanding
112,669,482
CFO
$-1,695.65 Mln
EBITDA
$-2,151.45 Mln
Net Profit
$-2,235.58 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zai Lab - ADR
| 29.6 | 26.4 | 21.4 | -23.0 | -14.0 | -32.0 | -- |
|
BSE Sensex*
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Zai Lab - ADR
| -32.6 | -4.1 | -11.0 | -51.2 | -53.6 | 225.4 | 79.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Zai Lab - ADR
|
22.9 | 2,732.0 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 3.8 |
| 4.0 | 455.5 | 73.2 | -67.8 | -82.1 | -65.5 | -- | 5.9 | |
| 19.6 | 1,263.0 | 0.0 | -147.4 | -29,734.7 | -150.3 | -- | 7.5 | |
| 29.1 | 1,966.4 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5.1 | 0.5 | |
| 14.6 | 2,706.5 | 550.0 | 458.1 | -3.3 | 45.9 | 5.9 | 2.2 | |
| 8.7 | 399.7 | 0.0 | -29.0 | -- | -20.4 | -- | 3.0 | |
| 17.1 | 1,224.6 | 403.3 | 22.8 | 3,081.6 | 9.1 | 433.5 | 4.4 | |
| 4.0 | 687.9 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.7 | |
| 8.0 | 355.7 | 0.6 | -88.6 | -15,110.2 | -90.3 | -- | 5.7 | |
| 5.3 | 535.3 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 4.1 |
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products... include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Turning Point Therapeutics, Inc. to develop and commercialize products containing repotrectinib; Entasis Therapeutics Holdings Inc. to develop and commercialize Durlobactam with Sulbactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for Tisotumab Vedotin; and strategic collaboration with Boehringer Ingelheim GmbH for the development of DLL3-targeting combination therapies for the treatment of small cell lung cancer and other neuroendocrine carcinomas. The company was incorporated in 2013 and is based in Pudong, China. Read more
Founder, Chairperson & CEO
Dr. Ying Du Ph.D.
Founder, Chairperson & CEO
Dr. Ying Du Ph.D.
Headquarters
Pudong
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Zai Lab Limited - ADR is $22.87 (NASDAQ) as of 22-Apr-2026 16:00 EDT. Zai Lab Limited - ADR has given a return of -14.04% in the last 3 years.
Since, TTM earnings of Zai Lab Limited - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-11.05
|
2.71
|
|
2024
|
-10.08
|
3.08
|
|
2023
|
-7.92
|
3.33
|
|
2022
|
-6.65
|
2.82
|
|
2021
|
-8.30
|
4.24
|
The 52-week high and low of Zai Lab Limited - ADR are Rs 44.34 and Rs 15.96 as of 23-Apr-2026.
Zai Lab Limited - ADR has a market capitalisation of $ 2,732 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Zai Lab Limited - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.